Medindia

X

Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference

Thursday, November 12, 2009 General News J E 4
Advertisement


BROOMFIELD, Colo., Nov. 11 Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at Lazard Capital Markets 6th Annual Healthcare Conference November 17-18, 2009 at the St. Regis Hotel in New York.

Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona(TM) on Tuesday, November 17 at 4:10 p.m. EST. A breakout session will follow Dr. Orndorff's presentation where he will be available for questions and answers.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.

For more information about Accera, please visit www.accerapharma.com.

Contacts: Accera, Inc. Steve Orndorff, Ph.D. President and CEO sorndorff@accerapharma.com Tiberend Strategic Advisors, Inc. (212) 827-0020 Andrew Mielach amielach@tiberendstrategicadvisors.com or Farrell Denby fdenby@tiberendstrategicadvisors.com

SOURCE Accera, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
House Health Reform Plan Will Benefit Millions of ...
S
Actress Debi Mazar Talks About her Family's Experi...